Diisocyanates and nonoccupational disease: A review

Archives of Environmental Health

Volumn 59, Issue 6, 2004, Pages 306-316

  Krone, Cheryl A ^a  

^a Applied Research Institute   (New Zealand)

Author keywords

Asthma; Consumer products; Diisocyanates; Exposure; Polyurethanes; Respiratory disease

Indexed keywords

ADHESIVE AGENT; CYANIC ACID DERIVATIVE; DIISOCYANATE DERIVATIVE; PAINT; POLYURETHAN; POLYURETHAN FOAM; SEALANT; UNCLASSIFIED DRUG;

ALLERGY; CHRONIC LUNG DISEASE; CONSUMER; ENVIRONMENTAL EXPOSURE; EPIDEMIC; HUMAN; OCCUPATIONAL ASTHMA; POPULATION RESEARCH; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; UNITED STATES;

ASTHMA; CHILD; CYANATES; ENVIRONMENTAL EXPOSURE; HOUSEHOLD PRODUCTS; HUMANS; POLYURETHANES; TOLUENE 2,4-DIISOCYANATE;

EID: 27144449572     PISSN: 00039896     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Rosenstock L, Cullen MR (Eds.). Textbook of Clinical, Occupational and Environmental Medicine. Philadelphia, PA: W.B. Saunders, 1994; pp 794-6.
2. Levy BS, Wegman DH (Eds). Occupational Health: Recognizing and Preventing Work-Related Diseases, 2nd ed. Boston/Toronto: Little, Brown and Co, 1988; p 640.
3. Tarlo SM, Liss GM. Diisocyanate-induced asthma: diagnosis, prognosis, and effects of medical surveillance measures. Appl Occup Environ Hyg 2002; 17(12): 902-8.
4. Ott MG, Diller WF, Jolly AT. Respiratory effects of toluene diisocyanate in the workplace: a discussion of exposure-response relationships. Crit Rev Toxicol 2003; 33(1):1-59.
5. Liu Q, Wisnewski AV. Recent developments in diisocyanate asthma. Ann Allergy Asthma Immunol 2003; 90(5 Suppl 2):35-41.
6. Randall D, Lee S (Eds). The Polyurethanes Book. New York: John Wiley, 2002; p 494.
7. Goossens A, Detienne T, Bruze M. Occupational allergic contact dermatitis caused by isocyanates. Contact Dermatitis 2002; 47:304-8.
8. Seguin P, Allard A, Cartier A, Malo JL. Prevalence of occupational asthma in spray painters exposed to several types of isocyanates, including polymethylene polyphenylisocyanate. J Occup Med 1987; 29(4): 340-4.
9. Selden AI, Belin L, Wass U. Isocyanate exposure and hypersensitivity pneumonitis-a report of a probable case and prevalence of specific immunoglobulin G antibodies among exposed individuals. Scand J Work Environ Health 1989; 15(3):234-7.
10. Carlton GN, England EC. Exposures to 1,6-hexamethylene diisocyanate during polyurethane spray painting in the U.S. Air Force. Appl Occup Environ Hyg 2000; 15(9):705-12.
11. Franklin PJ, Goldenberg WS, Ducatman AM, Franklin E. Too hot to handle: an unusual exposure of HDI in specialty painters. Am J Ind Med 2000; 37431-7.
12. Redlich CA, Stowe MH, Coren BA, et al. Diisocyanate-exposed auto body shop workers: a one-year follow-up. Am J Ind Med 2002; 42:511-8.
13. Lofgren DJ, Walley TL, Peters PM, et al. MDI exposure for spray-on truck bed lining. Appl Occup Environ Hyg 2003; 18:772-9.
14. Courtney D. Health hazards of soft soldering in the electronics industry. Rev Environ Health 1985; 5(1):1-26.
15. White WG, Morris MJ, Sugden E, et al. Isocyanate-induced asthma in a car factory. Lancet 1980; 1(8171):756-60.
16. Littorin M, Rylander L, Skarping G, et al. Exposure biomarkers and risk from gluing and heating of polyurethane: a cross sectional study of respiratory symptoms. Occup Environ Med 2000; 57:396-405.
17. Legris M, Trucot A, Lesage J, et al. Isocyanates: Contamination Through Skin Contact. Quebec, Canada: Hull, Association Québécoise de l'Hygiène, la Santé et la Sécurité au Travail; May 1996.
18. Johnson K. Fighting to educate Jewish Williamsburg about a health risk. New York Times. November 21, 2003.
19. De Zotti R, Muran A, Zambon F. Two cases of paraoccupational asthma due to toluene diisocyanate (TDI). Occup Environ Med 2000; 57(12):837-9.
20. Orloff KG, Batts-Osborne D, Kilgus T, et al. Antibodies to toluene diisocyanate in an environmentally exposed population. Environ Health Perspect 1998; 106(10):665-6.
21. Darcey D, Lipscomb HJ, Epling C, et al. Clinical findings for residents near a polyurethane foam-manufacturing plant. Arch Environ Health 2002; 57(3):239-46.
22. Wirpsza Z. Polyurethanes: Chemistry, Technology and Applications. New York: Ellis Horwood Publishers, 1993; p 517.
23. Landrock AH (Ed). Handbook of Plastic Foams: Types, Properties, Manufacture and Applications. Park Ridge, NJ: Noyes Publishers, 1995; p 488.
24. National Institutes of Health. MDI-Containing Household Products. http://householdproducts.nlm.nih. gov/cgi-bin/household/brands?tbl=chem&id= 656&query=isocyanate (accessed March 2, 2004).
25. Damant AP, Jickells SM, Castle L. Liquid chromatographic determination of residual isocyanate monomers in plastics intended for food contact use. J Assoc Official Anal Chem Intl 1995; 78(3):711-8.
26. Krone CA, Klingner T, Ely JTA. Polyurethanes and childhood asthma. Med Sci Monit 2003; 9(12):HY39-43.
27. Rando RJ, Poovey HG, Gibson RA. Evaluation of 9-methylamino- methylanthracene as a chemical label for total reactive isocyanate group: application to isocyanate oligomers, polyurethane prepolymers, and phosgene. J Liq Chrom 1995; 18:2743-63.
28. Krone CA, Ely JT, Klingner T, et al. Isocyanates in flexible polyurethane foams. Bull Environ Contam Toxicol 2003; 70(2):328-35.
29. Van Gheluwe P, Cole KC, Hebrard MJ, et al. Attenuated total reflectance infrared spectroscopic analysis of high index foams. J Cell Plastics 1987; 23:73-85.
30. Hugo JM, Spence MW, Lickly TD. The determination of the ability of Polyurethane foam to release diisocyanate into air. Appl Occup Environ Hyg 2000; 15:512-9.
31. Conte A, Cossi G. Gas chromatographic determination of free toluene diisocyanate in flexible urethane foams. J Chromatog 1981; 213:162-5.
32. Jedrzejczak K, Gaind VS. Determination of free toluene diisocyanates in flexible polyurethane foams using negative chemical-ionization mass spectrometry. Analyst 1993; 118:149-52.
33. Gagn TS, Lesage J, Ostiguy C, et al. Determination of unreacted 2,4-toluene diisocyanate (2,4TDI) and 2,6-toluene diisocyanate (2,6TDI) in foams at ultratrace level by using HPLC-CIS-MS-MS. Analyst 2003; 128:1447-51.
34. The Society of the Plastics Industry (SPII). Proposition 65 Compliance Workbook for TDI Exposure. Section 3. Calculating Exposure Levels: Summary. Washington, DC: SPII, 1990.
35. Occupational Safety and Health Administration (OSHA). Sampling for surface contamination. Technical Manual (OTM), section II, chapter 2. Cincinnati, OH: OSHA, 1997; http://www.osha-slc.gov/dts/osta/otm/otm_ii/otm_ ii_2.html#ii:2_2
36. Liu Y, Sparer J, Woskie SR, et al. Qualitative assessment of isocyanate skin exposure in auto body shops: a pilot study. Am J Ind Med 2000; 37(3):265-74.
37. Kelly TJ, Myers JD, Holdren MW. Testing of household products and materials for emission of toluene diisocyanate. Indoor Air 1999; 9(2):117-24.
38. Wirts M, Lnschen R, Lorenz W, et al. Isocyanatemission bei der Verarbeitung von Polyurethanklebstoffen. [Isocyanate emmision with the use of polyurethane adhesives.] Gefahrstoffe-Reinhalt Luft 2001; 61(5):181-6.
39. Wirts M, Salthammer T. Isocyanate emission from PUR adhesives: influence of temperature, monomer content, and curing mechanism. Environ Sci Technol 2002; 36(8):1827-32.
40. Wirts M, Grunwald D, Schulze D, et al. Time course of isocyanate emission from curing polyurethane adhesives. Atmosph Environ 2003; 37:5467-75.
41. Jarand CW, Akapo SO, Swenson LJ, et al. Diisocyanate emission from a paint product: a preliminary analysis. Appl Occup Environ Hyg 2002; 17(7):491-4.
42. Devor DE, Waalkes MP, Goering P, et al. Development of an animal model for testing human breast implantation materials. Toxicol Pathol 1993; 21(3):261-73.
43. Wang BH, Chang BW, Sargeant R, et al. Late capsular hematoma after breast reconstruction with polyurethane-covered implants. Plast Reconstr Surg 1998; 102(2): 450-2.
44. Shanklin DR, Smalley DL. Dynamics of wound healing after silicone device implantation. Exp Mol Pathol 1999; 67(1):26-39.
45. Katzin WE, Feng LJ, Abbuhl M, et al. Phenotype of lymphocytes associated with the inflammatory reaction to silicone gel breast implants. Clin Diagn Lab Immunol 1996; 3(2):156-61.
46. Strachan DP, Carey IM. The home environment and severe asthma in adolescence: a population based case-control study. Br Med J 1995; 311:1053-6.
47. Herrick CA, Xu L, Wisnewski AV, et al. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J Allergy Clin Immunol 2002; 109:873-8.
48. Sepai O, Henschler D, Czech S, et al. Exposure to toluenediamines from polyurethane-covered breast implants. Toxicol Lett 1995; 77(1-3):371-8.
49. Hester TR Jr, Ford NF, Gale PJ, et al. Measurement of 2,4-toluenediamine in urine and serum samples from women with Même or Replicon breast implants. Plast Reconstr Surg 1997; 100(5):1291-8.
50. Sabbioni G, Hartley R, Schneider S. Synthesis of adducts with amino acids as potential dosimeters for the biomonitoring of humans exposed to toluenediisocyanate. Chem Res Toxicol 2001; 14(12):1573-83.
51. Kaaria K, Hirvonen A, Norppa H, et al. Exposure to 2,4- and 2,6-toluene diisocyanate (TDI) during production of flexible foam: determination of airborne TDI and urinary 2,4- and 2,6-toluenediamine (TDA). Analyst 2001; 126(7):1025-31.
52. Anonymous. Adverse reactions associated with midline catheters-United States, 1992-1995. Morb Mortal Weekly Rep 1996; 45(5):101-3.
53. Vanek VW, Kupensky DT, Thomson DJ. Hypersensitivity-like reactions related to insertion of aquavene-based midline and PICC catheters. J Intraven Nurs 1997; 20(1):23-7.
54. Silverstein B, Witkin KM, Frankos VH, et al. Assessing the role of the biomaterial Aquavene in patient reactions to Landmark midline catheters. Regul Toxicol Pharmacol 1997; 25(1):60-7.
55. Weyel DA, Rodney BS, Alarie Y. Sensory irritation, pulmonary irritation, and acute lethality of a polymeric isocyanate and sensory irritation of 2,6-toluene diisocyanate. Toxicol Appl Pharmacol 1982; 64(3):423-30.
56. Anderson RC, Anderson JH. Respiratory toxicity of mattress emissions in mice. Arch Environ Health 2000; 55(1):38-43.
57. Karaman O, Uguz A, Uzuner N. Risk factors in wheezing infants. Pediatr Int 1999; 41:147-50.
58. Strachan D, Carey IM. Reduced risk of wheezing in children using feather pillows is confirmed. Br Med J 1997; 314:518.
59. Frosch AC, Sandhu G, Joyce R, et al. Prevalence of rhinitis, pillow type and past and present ownership of furred pets. Clin Exp Allergy 1999; 29:457-60.
60. Yemaneberhan H, Bekele Z, Venn A, et al. Prevalence of wheeze and asthma and relation to atopy in urban and rural Ethiopia. Lancet 1997; 350:85-90.
61. Siebers R, Fitzharris P, Crane J. Feather bedding and allergic disease in children: a cover story? Clin Exp Allergy 2002; 32:1119-23.
62. Butland BK, Strachan DP, Anderson HR. The home environment and asthma symptoms in childhood: two population-based case-control studies 13 years apart. Thorax 1997; 52:61 8-24.
63. Jones KP, Rolf S, Stringl C, et al. The allergenicity of feather bedding material. Allergy 2002; 57:266.
64. Centers for Disease Control and Prevention. Surveillance for asthma-United States, 1960-1995. CDC Surveill Summ 1998; 47:1-28.
65. Public Health Service. Morbidity and Mortality: 2004 Chart Book on Cardiovascular, Lung and Blood Diseases. Washington, DC: U.S. Department of Health and Human Services, 2004; 〈http://www.nhlbi.nih.gov/ resources/docs/04_chtbk.pdf〉 Accessed June 19, 2004.
66. Perez-Peia R. Study finds asthma in 25% of children in central Harlem. New York Times. April 19, 2003; 〈http://www.nytimes.eom/2003/04/19/ nyregion/19ASTH. html?ex=1051794862&ei=1 &en=b844010d8e0674b1〉 Accessed April 20, 2003.
67. Broadfield E, McKeever TM, Scrivener S, et al. Increase in the prevalence of allergen skin sensitization in successive birth cohorts. J Allergy Clin Immunol 2002; 109(6): 969-74.
68. Jinot J, Bayard S. Respiratory health effects of exposure to environmental tobacco smoke. Rev Environ Health 1996; 11(3):89-100.
69. Steerenberg PA, Van Amsterdam JG, Vandebriel RJ, et al. Environmental and life-style factors may act in concert to increase the prevalence of respiratory allergy including asthma. Clin Exp Allergy 1999; 10:1303-8.
70. Peden DB. Development of atopy and asthma: candidate environmental influences and important periods of exposure. Environ Health Perspect 2000; 108(suppl 3):475-82.
71. Holt PG. The role of genetic and environmental factors in the development of T-cell-mediated allergic disease in early life. Paediatr Respir Rev 2004; 5(suppl A):S27-S30.
72. Handzel ZT. Effects of environmental pollutants on airways, allergic inflammation, and the immune response. Rev Environ Health. 2000; 15(3):325-36.
73. Muranaka M, Suzuki S, Koizumi K, et al. Adjuvant activity of diesel exhaust particulates for the production of IgE antibody in mice. J Allergy Clin Immunol 1986; 77:616-23.
74. Institute of Medicine (US), Committee on the Assessment of Asthma and Indoor Air. Clearing the Air: Asthma and Indoor Air Exposures. Washington, DC: National Academy Press, 2000.
75. Braun-Fahrlander C. Environmental exposure to endotoxin and other microbial products and the decreased risk of childhood atopy: evaluating developments since April 2002. Curr Opin Allergy Clin Immunol 2003; 3(5):325-9.
76. Tang MLK. Is prevention of childhood asthma possible? Allergens, infections and animals. Med J Aust 2002; 177:575-7.
77. Prescott SL, Macaubas C, Smallacombe T, et al. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999; 353(9148):196-200.
78. Petsonk EL, Wang ML, Lewis DM, et al. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 2000; 118(4):1183-93.
79. Maestrelli P, Di Stefano A, Occari P, et al. Cytokines in the airway mucosa of subjects with asthma induced by toluene diisocyanate. Am J Respir Crit Care Med 1995; 151:607-12.
80. Tarlo SM, Liss GM, Dias C, et al. Assessment of the relationship between isocyanate exposure levels and occupational asthma. Am J Ind Med 1997; 32:517-21.
81. Karol MH, Dixon C, Brady M, et al. Immunologic sensitization and pulmonary hypersensitivity by repeated inhalation of aromatic isocyanates. Toxicol Appl Pharmacol 1980; 53:260-70.
82. Weill H, Butcher BT, Dharmarajan V, et al. Respiratory and immunologic evaluation of isocyanate exposure in a new manufacturing plant. Final report. National Institute of Occupational Safety and Health (NIOSH) Publication No. 81-125. NIOSH Technical Report. Washington, DC: US Government Printing Office, 1981.
83. American Conference of Governmental Industrial Hygienists (ACGIH). Documentation of the Threshold Limit Values and Biological Exposure Indices, 5th ed. Cincinnati, OH: ACGIH, 1986.
84. Wegman D, Pagnatto L, Fine L, et al. A dose-response relationship in TDI workers. J Occup Med 1974; 16:258-60.
85. Kimber I. The role of the skin in the development of chemical respiratory hypersensitivity. Toxicol Lett 1996; 86:89-92.
86. Jang A, Choi I, Koh Y, et al. An increase in airway hyperresponsiveness among workers exposed to methylene diphenyldiisocyanate compared to workers exposed to toluene diisocyanate at a petrochemical plant in Korea. Am J Ind Med 2000; 37:663-7.
87. Karol MH, Hauth BA, Riley EJ, et al. Dermal contact with toluene diisocyanate (TDI) produces respiratory tract hypersensitivity in guinea pigs. Toxicol Appl Pharmacol 1981; 58:221-30.
88. Bickis U. Investigation of Dermally Induced Airway Hyperreactivity to Toluene Diisocyanate in Guinea Pigs [dissertation]. Kingston, Canada: Queens University, Dept. of Pharmacology and Toxicology; November 1994.
89. Rattray NJ, Botham PA, Hext PM, et al. Induction of respiratory hypersensitivity to diphenylmethane-4-4 Æ-diisocyanate (MDI) in guinea pigs: Influence route of exposure. Toxicology 1994; 88:15-30.
90. Lemanske RF Jr. Issues in understanding pediatric asthma: epidemiology and genetics. J Allergy Clin Immunol 2002; 109(6 suppl):S521-S524.
91. Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol 2003; 111(3):S799-S804.
92. Sudo N, Sawamura S-A, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997; 159:1739-45.
93. Peroni DG, Chatzimichail A, Boner AL. Food allergy: what can be done to prevent progression to asthma? Ann Allergy Asthma Immunol 2002; 89(6 suppl 1):44-51.
94. Lack G, Fox D, Northstone K, et al. Avon Longitudinal Study of Parents and Children Study Team. Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003; 348(11):977-85.
95. Zissu D, Binet S, Limasset J-D. Cutaneous sensitization to some polyisocyanate prepolymers in guinea pigs. Contact Dermatitis 1998; 39:248-51.
96. Herrick CA, Das J, Xu L, et al. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J Allergy Clin Immunol 2003; 111:1087-94.
97. Maestrelli P, Occari P, Turato G, et al. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin Exp Allergy 1997; 27:1292-8.
98. Mapp CE, Balboni A, Baricordi R, et al. Human leukocyte antigen associations in occupational asthma induced by isocyanates. Am J Respir Crit Care Med 1997; 156:5139-5143.
99. Denda M, Wood LC, Emami S, et al. The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape stripping cannot be attributed to increased water loss. Arch Dermatol Res 1996; 288:230-8.
100. Tee RD, Cullinan P, Welch J, et al. Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101(5):709-15.
101. Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GTSP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109:867-72.
102. Suoniemi I, Bjorksten F, Haahtela T. Dependence of immediate hypersensitivity in the adolescent period on factors encountered in infancy. Allergy 1981; 36(4):263-8.
103. Vanto T, Koivikko A. Dog hypersensitivity in asthmatic children. A clinical study with special reference to the relationship between the exposure to dogs and the occurrence of hypersensitivity symptoms. Acta Paediatr Scand 1983; 72(4):571-5.
104. Popp W, Rauscher H, Serti K, et al. Risk factors for sensitization to furred pets. Allergy 1990; 45(1):75-79.
105. Platts-Mills T, Vaughan J, Squillace S, et al. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357(9258):752-6.
106. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6-7 years of age. JAMA 2002; 288:963-72.
107. Remes ST, Castro-Rodreiguez JA, Holberg J, et al. Dog exposure in infancy decreases the subsequent risk of frequent wheeze but not of atopy. J Allergy Clin Immunol 2001; 108:509-15.
108. Almqvist C, Egmar AC, Hedlin G, et al. Direct and indirect exposure to pets-risk of sensitization and asthma at 4 years in a birth cohort. Clin Exp Allergy 2003; 33(9):1190-7.
109. Nafstad P, Nystad W, Jaakkola JJ. The use of a feather quilt, childhood asthma and allergic rhinitis: a prospective cohort study. Clin Exp Allergy 2002; 32(8):1150-4.
110. Zock J-P, Jarvis D, Luczynska C, et al. Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey. J Allergy Clin Immunol 2002; 110(2):285-92.
111. Gotzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. Br Med J 1998; 317:1105-10.
112. Woodcock A, Forster L, Matthews E, et al. Control of exposures to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349(3):225-36.
113. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003; 349(3):237-46.
114. Piirila PL, Nordman H, Keskinen HM, etal. Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane diisocyanate-, and toluene diisocyanate-induced asthma. Am J Respir Crit Care Med 2000; 162:516-22.
115. Pisati G, Baruffini A, Zedda S. Toluene diisocyanate induced asthma: outcome according to persistence or cessation of exposure. Br J Ind Med 1993; 50(1):60-4.
116. Park HS, Frew AJ. Genetic markers for occupational asthma. J Allergy Clin Immunol 2002; 109:774-6.
117. Park HS, Nahm DH. Prognostic factors for TDI-induced occupational asthma after removal from exposure. Clin Exp Allergy 1997; 27:1145-50.
118. Padoan M, Pozzato V, Simoni M, et al. Long-term follow-up of toluene diisocyanate-induced asthma. Eur Respir J 2003; 21(4):637-40.
119. Keskinen H, Tupasela O, Tikkainen U, et al. Experiences of specific IgE in asthma due to diisocyanates. Clin Allergy 1988; 18:597-604.
120. Schwab M, McDermott A, Spengler JD. Using longitudinal data to understand children's activity patterns in an exposure context: data from the Kanawha County Health Study. Environ Int 1992; 18:173-89.